Trial Profile
A Pivotal, Open-Label, Randomized, Crossover Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics; Registrational
- Sponsors NeuroDerm
- 20 Nov 2018 Status changed to withdrawn prior to enrolment due to decision to change in study design.
- 13 Mar 2018 New trial record